Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

Phase 1 Completed 40 enrolled Quantum Biopharma Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.) · collab

RandomizedSequentialTriple-blindTreatment

Summary

This study aims to determine the safety, tolerability, and pharmacokinetics of single doses of Lucid-21-302 in healthy adult volunteers. This study will also investigate the effects of food in healthy volunteers.

Timeline

Start: 2023-03-22
Primary completion: 2023-07-29
Completion: 2023-07-29

Publications

Background Tejeda EJC, Bello AM, Wasilewski E, Koebel A, Dunn S, Kotra LP. Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis. J Med Chem. 2017 Nov 9;60(21):8876-8887. doi: 10.1021/acs.jmedchem.7b01102. Epub 2017 Oct 30.
Background Caprariello AV, Rogers JA, Morgan ML, Hoghooghi V, Plemel JR, Koebel A, Tsutsui S, Dunn JF, Kotra LP, Ousman SS, Wee Yong V, Stys PK. Biochemically altered myelin triggers autoimmune demyelination. Proc Natl Acad Sci U S A. 2018 May 22;115(21):5528-5533. doi: 10.1073/pnas.1721115115. Epub 2018 May 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lucid-21-302	Small molecule	—	—

Indications

No indication recorded.